KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities: 2017-2025

Historic Total Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $2.8 billion.

  • Amneal Pharmaceuticals' Total Non-Current Liabilities rose 15.86% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 15.86%. This contributed to the annual value of $2.4 billion for FY2024, which is 5.79% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Total Non-Current Liabilities of $2.8 billion as of Q3 2025, which was up 17.68% from $2.4 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $2.9 billion during Q2 2021, with a 5-year trough of $2.3 billion in Q1 2025.
  • Over the past 3 years, Amneal Pharmaceuticals' median Total Non-Current Liabilities value was $2.6 billion (recorded in 2023), while the average stood at $2.6 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Total Non-Current Liabilities decreased by 12.44% in 2024 and then climbed by 15.86% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $2.9 billion in 2021, then declined by 1.42% to $2.8 billion in 2022, then dropped by 9.62% to $2.6 billion in 2023, then declined by 5.79% to $2.4 billion in 2024, then rose by 15.86% to $2.8 billion in 2025.
  • Its Total Non-Current Liabilities stands at $2.8 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.3 billion for Q1 2025.